{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"131"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","groups":[{"description":"Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - China"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"China safety population included all randomized China participants who received any amount of study drug with participants grouped according to the treatment the participant actually received.","reportingStatus":"POSTED","timeFrame":"Up to end of study (up to approximately 56 months)","title":"Number of Participants With Adverse Events (AEs) in the China Population","type":"SECONDARY","unitOfMeasure":"Participants"}